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Summary-Although negative symptoms were traditionally considered to be unresponsive to neur- 
oleptic medication, recent studies have demonstrated that negative symptoms do improve during 
neuroleptic treatment and that such improvement tends to occur concurrently with improvement 
in positive symptoms. Clozapine is an atypical neuroleptic that is effective in a significant proportion 
of otherwise neuroleptic-nonresponsive schizophrenic patients; in contrast to conventional neur- 
oleptics, clozapine is also purported to possess unique efficacy in the amelioration of negative 
symptoms. How clozapine-associated reduction in negative symptoms relates to change in positive 
symptoms is not clear. To study the relationship between change in positive and negative symptoms 
during clozapine treatment, we monitored symptomatology in 40 DSM-III-R schizophrenic patients 
before and about 8 weeks after a trial of clozapine. Both positive and negative symptoms improved 
significantly. There was a significant correlation (r = .63, p c.01) between change in positive 
symptoms and change in negative symptoms; as with conventional neuroleptics, negative symptoms 
improved concomitantly with positive symptoms during clozapine treatment. Clozapine’s apparent 
greater efficacy on negative symptoms may be related to its greater efficacy on positive symptoms 
in otherwise neuroleptic-refractory patients and its lesser propensity to cause extrapyramidal side- 
effects. 
Introduction 
ALTHOUGH negative schizophrenic symptoms have traditionally been considered to be 
poorly responsive to neuroleptic treatment (Crow, 1980; Andreasen et al., 1982) several 
recent studies have demonstrated that negative symptoms do improve in the course of 
neuroleptic treatment of schizophrenic patients (Breier et al., 1987; van Kammen et al., 
1987; Meltzer, 1990; Tandon et al., 1990; Tandon et al., 1993). Furthermore, this 
improvement in negative symptoms has been found to occur concomitantly with improve- 
ment in positive symptoms (van Kammen et al., 1987; Meltzer, 1990; Tandon et al., 1990; 
Tandon et al., 1993); with conventional neuroleptic treatment, improvement in negative 
symptoms generally does not occur independently of improvement in positive symptoms. 
Clozapine is an atypical antipsychotic agent with a unique therapeutic profile (Kane et 
al., 1988; Lader, 1992): in contrast to conventional neuroleptics, clozapine is more effective 
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in decreasing positive and negative symptoms in treatment-refractory schizophrenic patients 
and causes fewer extrapyramidal side-effects (EPS) and tardive dyskinesia. It has been 
found to produce greater improvement in negative symptoms than typical neuroleptics 
(Kane et al., 1988; Meltzer, 1992). Meltzer (1990, 1991) observed that negative symptoms 
improved independently of change in positive symptoms in schizophrenic patients treated 
with clozapine; he noted that clozapine differed from conventional neuroleptics in this 
regard. The question of whether the observed greater efficacy of clozapine in treating 
negative symptoms is related to its greater efficacy in treating positive symptoms in this 
population of schizophrenic patients or whether the clozapine-associated reduction in 
negative symptoms occurs independently of such improvement has obvious patho- 
physiological and clinical importance. To study this question, we assessed positive and 
negative symptoms in a sample of 40 schizophrenic patients before and about 8 weeks after 
an open clinical trial of clozapine. 
Materials and Methods 
The sample consisted of 40 schizophrenic patients who received a clinical trial of clozapine 
for a minimum of 8 weeks. Patients were recruited from the University of Michigan 
Schizophrenia Program, principally through its affiliation with the Lenawee County Com- 
munity Mental Health Center. Diagnostic evaluation included an extensive history, review 
of all clinical records, clinical observations, and a structured interview using the Schedule 
for Affective Disorders and Schizophrenia (SADS; Endicott and Spitzer, 1978). All patients 
met both DSM-ITT-R criteria (APA, 1987) and Research Diagnostic Criteria (RDC, Spitzer 
et al., 1978) for schizophrenia. The final sample of 40 patients consisted of 28 men and 12 
women with a mean + SD age of 37 f 10 years and a mean duration of illness of 13 f 8 
years. 
Patients were on treatment with one of several different neuroleptics prior to beginning 
treatment with clozapine. All but four were on treatment with either haloperidol, flu- 
phenazine, or thiothixene with/without anticholinergic medication prior to starting treat- 
ment with clozapine; no patient was on a depot neuroleptic. Of the 44 patients who 
started the clozapine trial, 4 dropped out before 8 weeks because of intolerable side-effects. 
Clozapine was started on an inpatient basis in about half the patients and on an outpatient 
basis in the other half. Clinically-determined treatment-refractoriness was the principal 
reason for the clozapine trial in this group of patients. A titration protocol was utilized to 
gradually increase the dose of clozapine to 300 mg/day generally by the end of the second 
week of the trial (although a slower titration was utilized in some patients). Patients were 
generally tapered off their previous neuroleptic over a period of l-3 weeks as their dosage 
of clozapine was being titrated upwards. Clinicians were permitted to modify the dose of 
clozapine based on clinical response and the patient’s ability to tolerate the medication. At 
the end of 8 weeks, the mean f SD dose of clozapine was 405 + 120 mg per day. 
Baseline clinical ratings were performed l-3 days before patients received their first dose 
of clozapine. Except for one patient who was drug-free, all others were receiving some 
neuroleptic at this timepoint. About 8 weeks after beginning treatment with clozapine 
(range = 8-10 weeks), patients received another set of clinical ratings. Patients were rated 
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on the Brief Psychiatric Rating Scale (BPRS, Overall & Gorham, 1962) and the Scale for 
the Assessment of Negative Symptoms (SANS, Andreasen, 1983) at both timepoints. 
Assessment of global severity was made by the 18-item BPRS total score. Positive symptoms 
were assessed by the sum of the following four BPRS items: conceptual disorganization, 
suspiciousness, hallucinatory behavior, and unusual thought content; this cluster of BPRS 
items was utilized to define “key” positive symptoms in the pivotal multicenter clinical trial 
of clozapine in treatment-refractory schizophrenia (Kane et al., 1988). Negative symptoms 
were assessed by the SANS sum of global scores. 
Paired two-tailed students’ t-tests were performed to compare the symptom ratings at 
baseline to those eight weeks after initiating clozapine treatment. Correlation analysis (using 
Pearson product-moment correlations) between change in positive symptoms and change 
in negative symptoms was conducted to evaluate the covariance of these symptom clusters. 
Results 
Both positive and negative symptoms improved significantly (p < .Ol) with clozapine 
treatment (Table 1). Use of the BPRS “ANER” factor (emotional withdrawal, motor 
Table 1 
Positive and Negative Symptom Ratings at Baseline and Following 8 Weeks of Treatment With Clozapine (N = 40) 










(SANS sum of global scores) 
53.5 k9.8 43.3 +9.2 p <.Ol 19.1% 
16.Ok3.6 12.4k3.5 p <.Ol 22.5% 
13.8*4.5 11.0+4.1 p <.Ol 20.3% 
retardation, and blunted affect) instead of the SANS sum of global scores to define negative 
symptoms did not alter the findings. Change in negative symptoms was significantly cor- 
related to change in positive symptoms (Fig. 1). 
Discussion 
In agreement with findings of other studies, these data confirm that both positive and 
negative schizophrenic symptoms improve significantly over the course of clozapine treat- 
ment. The significant correlation between change in positive and negative symptoms during 
clozapine treatment noted in this study is similar to the pattern observed with conventional 
neuroleptics. The correlated improvement in positive and negative symptoms during 8- 
weeks clozapine treatment suggests that mechanisms underlying such improvement are 
linked, although it is conceivable that completely unrelated mechanisms (with similar time 
courses) may underlie improvement in positive and negative symptoms associated with 
clozapine treatment. It should be noted that the baseline from which change in positive and 
negative symptoms was assessed was not medication-free as patients were on some typical 
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Figure I 
neuroleptic treatment immediately prior to the clozapine trial; consequently, withdrawal 
from conventional neuroleptics may have contributed to the observed changes in addition 
to the treatment with clozapine. 
The correlation between change in positive symptoms and change in negative symptoms 
observed in this study differs from the findings of Meltzer (1991) who noted an absence of 
any such relationship. Although the precise reason for this discrepancy is unclear, it may 
partly be related to differences in sample characteristics and the instruments used to assess 
negative symptoms in these studies. 
If confirmed, the covariance of positive and negative symptoms in the course of clozapine 
treatment could have important pathophysiological and treatment implications. Firstly, it 
suggests that clozapine does not differ from typical neuroleptics in this regard; i.e., there is 
one less aspect to its “unique” clinical profile that needs explanation. It is critical that 
clozapine’s particular therapeutic profile be carefully defined as one attempts to better 
understand its hitherto unknown mechanism of action (Tandon & Kane, 1993). Secondly, 
these data suggest that while clozapine is effective in the treatment of primary nonenduring 
negative symptoms (negative symptoms associated with positive symptomsPsometimes 
called negative symptoms secondary to positive symptoms), its efficacy in treating deficit 
negative symptoms (Carpenter et al., 1988) is questionable. In fact, Breier et al. (1992) note 
that clozapine appears to have a deleterious effect on deficit negative symptoms. Thirdly, 
the covariance of positive and negative symptoms during conventional and clozapine 
treatment indicates that common or related pathophysiological mechanisms may underly 
positive and primary nonenduring negative symptoms in schizophrenia (Tandon & Greden, 
1989). 
How then does one explain the finding of a greater improvement in negative symptoms 
during treatment with clozapine than with conventional neuroleptics (Itoh et al., 1974; Kane 
et al., 1988; Meltzer, 1992)? It is well-known that negative symptoms are a heterogeneous 
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construct and that negative symptoms (as measured) have multiple contributing factors 
(Carpenter et al., 1985, 1988; Moller, 1993; Tandon & Greden, 1991). The apparent greater 
efficacy of clozapine in treating negative symptoms may be related to its greater efficacy in 
treating positive symptoms in otherwise treatment-refractory patients and because of its 
lesser propensity to cause EPS (Fig. 2). While the hypothesized differences in various 
components of negative symptoms under the three conditions depicted in Fig. 2 are some- 
what speculative, they are consistent with the current conceptualization of negative symp- 
toms in schizophrenia (Carpenter, 1991; Tandon & Greden, 1991) and can explain observed 
differences in negative symptom severity under conditions of no treatment, classical neur- 
oleptic treatment, and clozapine treatment. 
In comparison to the drug-free state, as positive symptoms improve with neuroleptic 
treatment, that component of negative symptoms associated with positive symptoms 
improves as well. In otherwise neuroleptic-refractory patients, clozapine effects greater 
improvement in positive symptoms than conventional neuroleptics (Kane et al., 1988); one 
would expect a corresponding greater reduction in negative symptoms as well. While 
primary nonenduring negative symptoms decrease in the course of neuroleptic treatment, 
that component of negative symptoms reflecting extrapyramidal side-effects (EPS) increases. 
Since clozapine has a significantly lesser propensity to cause EPS than conventional neur- 
oleptics (Kane et al., 1988; Lader, 1992; Meltzer, 1992), clozapine would be predicted to 
cause a lesser increase in this component of negative symptoms than typical neuroleptics. 
As graphically depicted in Fig. 2, one would expect the observation of a greater reduction 
in negative symptoms with clozapine than with conventional neuroleptics. In this depiction, 
components of negative symptoms related to deficit, environmental deprivation and 
depression are assumed to be constant in the untreated, typical neuroleptic and clozapine 
treatment conditions. 
These data indicate that clozapine is similar to typical neuroleptics with regard to 
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improvement in negative symptoms and their covariance with positive symptoms. In com- 
parison to typical neuroleptics, the apparent greater efficacy of clozapine in treating negative 
symptoms may be related to its greater efficacy in treating positive symptoms in treatment- 
refractory patients and its lower propensity to cause EPS. 
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